Hangzhou Jiuyuan Gene Engineering Co Ltd
Company Profile
Business description
Hangzhou Jiuyuan Gene Engineering Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, It has built a diversified product portfolio comprising eight marketed products, including China’s first recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair material, Guyoudao, and over ten product candidates, including the first semaglutide biosimilar in China to have obtained an IND approval and filed an NDA, JY29-2.
Contact
No. 23, Eighth Street Baiyang Street
Qiantang District
Zhejiang Province
Hangzhou
CHNT: +86 57186910099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,467
Stocks News & Analysis
stocks
2 undervalued ASX shares report
stocks
Turmoil at WiseTech
video
What does the RBA rate cut mean for investors?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,498.00 | 62.10 | -0.73% |
CAC 40 | 8,090.99 | 63.52 | -0.78% |
DAX 40 | 22,425.93 | 138.37 | 0.62% |
Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
FTSE 100 | 8,658.98 | 0.39 | -0.00% |
HKSE | 23,227.63 | 113.98 | -0.49% |
NASDAQ | 19,286.93 | 237.08 | -1.21% |
Nikkei 225 | 38,281.45 | 495.49 | -1.28% |
NZX 50 Index | 12,307.27 | 224.45 | -1.79% |
S&P 500 | 5,983.25 | 29.88 | -0.50% |
S&P/ASX 200 | 8,251.90 | 56.30 | -0.68% |
SSE Composite Index | 3,367.25 | 5.77 | -0.17% |